6149f1beaa40346ca98899a0 adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non-small-cell-lung-cancer-impower010-a-randomised-multicentre-open-label-phase-3-trial 2021-09-21T20:18:14.089Z 5e283dc93b5e750642253e50 8f13726e-5635-471f-ad3c-fc910a6ac2b1 eb492904-ca53-4abb-9e61-15871d3b1cb9 mas_evidence_types:Randomised%20controlled%20trials Primary research RCT (n=1005) found after median 32·2 months follow, atezolizumab linked to significant improvements in disease-free survival vs. best supportive care, particularly in stage II–IIIA patients with tumours expressing PD-L1 on ≥1% tumour cells (HR 0·66;95% CI 0·50–0·88;p=0·0039). <p>Commentary suggests IMpower010 study represents an important step forward and adjuvant atezolizumab should be a new standard of care for patients with surgically resected, PD-L1-positive stage II&ndash;IIIA non-small-cell lung cancer (NSCLC) after completion of adjuvant chemotherapy, with particular emphasis on those patients with PD-L1 expression on 50% or more tumour cells. It notes that in the near future, the therapeutic landscape for resectable NSCLC is likely to become more complicated as additional data emerge from other, ongoing studies of immune checkpoint inhibitors in the adjuvant setting and parallel studies evaluating neoadjuvant approaches.</p> https://www.medicinesresources.nhs.uk/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non-small-cell-lung-cancer-impower010-a-randomised-multicentre-open-label-phase-3-trial.html <p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02100-0/fulltext">Comment</a></p> https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext 2021-09-20T00:00:00Z 2021-09-21T14:52:46.497Z